Evidence map›Paper›PMID 38468222›Full record

ArticleBMC neuroscience2024

Administration methods and dosage of poly(lactic acid)-glycol intervention to myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalitis mice.

Amy E Wright, Shuhei Nishiyama, Patrick Han, Philip Kong, Michael Levy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Amy E WrightDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Shuhei NishiyamaDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA. snishym@med.tohoku.ac.jp.ORCID 0000-0002-0248-1595
Patrick HanHarvard Medical School, Boston, MA, USA.
Philip KongStatera Therapeutics, New Haven, CT, USA.
Michael LevyDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Harvard University · USMassachusetts General Hospital · US

Funding

Spatiotemporal tuning of myelin antigens and rapamycin for enhanced antigen-specific immune tolerance in multiple sclerosis.R43AI157959 · NIAID · STATERA THERAPEUTICS INC. · PI CATINO, JOSEPH J, LEVY, MICHAEL · 2021 to 2021
$295k
NIAID NIH HHS R43 AI157959NIH HHS R43AI157959
6 · The paper itself

Abstract

backgroundMyelin oligodendrocyte glycoprotein-associated disorders (MOGAD) is an autoimmune central nervous system disease. Antigen-specific immune tolerance using nanoparticles such as Polylactic-co-glycolic acid (PLGA) have recently been used as a new therapeutic tolerization approach for CNS autoimmune diseases. We examined whether MOG

resultsMice with EAE that were injected intraperitoneally with MOG

conclusionIntraperitoneal administration of PLGA resulted in dose-dependent and longer-lasting immune tolerance than subcutaneous administration. The induction of immune tolerance using PLGA may represent a future therapeutic option for patients with MOGAD.

Indexed as

EncephalitisEncephalomyelitis, Autoimmune, ExperimentalHashimoto DiseasePolyestersAnimalsGlycolsHumansImmunoglobulin GMiceMice, Inbred C57BLMyelin-Oligodendrocyte GlycoproteinSirolimusGlycolsImmunoglobulin GMyelin-Oligodendrocyte GlycoproteinPolyesterspoly(lactide)SirolimusEAEMOGADMOG-IgGPLGA

Identifiers

PMID38468222
PMCPMC10929165
OpenAlexW4392644073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.